Johnson and Johnson Pharmacy

FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

CNN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Business Insider · 2d

JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression

Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.

Forbes1y

Johnson And Johnson Stock Slips After Missing The Mark For Earnings

Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories hit the press Even ...

Hosted on MSN1mon

Johnson & Johnson sues Cigna units for alleging draining funds intended for copays: report

Johnson & Johnson (NYSE ... According to the report, J&J added Cigna’s Express Scripts pharmacy benefits manager and specialty pharmacy Accredo as defendants in an amended lawsuit it filed ...

The Independent26d

Man sues Johnson & Johnson for $25m claiming talcum powder killed his wife

A man in Maine is suing pharmeceutical giant Johnson & Johnson for $25 million over the death of his wife, claiming that use of its “dangerous and defective” talcum powder caused her death.

CNN6y

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and ...

Business Insider28d

Johnson & Johnson licensing STAT6 program from Kaken Pharmaceutical

Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results